Evolus, Inc. (EOLS)

Market Cap	660.03M
Revenue (ttm)	266.27M
Net Income (ttm)	-50.42M
Shares Out	63.59M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	657,759
Open	10.62
Previous Close	10.79
Day's Range	10.22 - 10.62
52-Week Range	8.67 - 17.82
Beta	0.97
Analysts	Strong Buy
Price Target	23.75 (+129.03%)
Earnings Date	May 6, 2025

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 332
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $23.75, which is an increase of 129.03% from the latest price.

Price Target

$23.75

(129.03% upside)

Analyst Consensus: Strong Buy